MILTUXIMAB Trademark

Trademark Overview

On Wednesday, September 13, 2017, a trademark application was filed for MILTUXIMAB with the United States Patent and Trademark Office. The USPTO has given the MILTUXIMAB trademark a serial number of 79219018. The federal status of this trademark filing is REGISTERED as of Tuesday, May 22, 2018. This trademark is owned by Minomic International Ltd.. The MILTUXIMAB trademark is filed in the Pharmaceutical Products category with the following description:

pharmaceutical preparations for the diagnosis, treatment, or prevention of cancer, oncological disorders, auto-immune diseases, and inflammation diseases
miltuximab

General Information

Serial Number79219018
Word MarkMILTUXIMAB
Filing DateWednesday, September 13, 2017
Status700 - REGISTERED
Status DateTuesday, May 22, 2018
Registration Number5472258
Registration DateTuesday, May 22, 2018
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 6, 2018

Trademark Statements

Goods and Servicespharmaceutical preparations for the diagnosis, treatment, or prevention of cancer, oncological disorders, auto-immune diseases, and inflammation diseases

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, October 25, 2017
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameMinomic International Ltd.
Party Type30 - Original Registrant
Legal Entity Type16 - Limited Liability Company
AddressAU
Party NameMinomic International Ltd.
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressAU
Party NameMinomic International Ltd.
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressAU

Trademark Events

Event DateEvent Description
Friday, October 30, 2020NEW REPRESENTATIVE AT IB RECEIVED
Thursday, October 1, 2020APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Thursday, October 1, 2020TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, October 1, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, October 1, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, October 1, 2020TEAS CHANGE OF OWNER ADDRESS RECEIVED
Saturday, September 29, 2018FINAL DECISION TRANSACTION PROCESSED BY IB
Wednesday, September 5, 2018FINAL DISPOSITION NOTICE SENT TO IB
Wednesday, September 5, 2018FINAL DISPOSITION PROCESSED
Wednesday, August 22, 2018FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Tuesday, May 22, 2018REGISTERED-PRINCIPAL REGISTER
Tuesday, March 6, 2018OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 6, 2018PUBLISHED FOR OPPOSITION
Wednesday, February 14, 2018NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Saturday, January 27, 2018REFUSAL PROCESSED BY IB
Thursday, January 25, 2018APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, January 24, 2018TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, January 23, 2018CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, January 23, 2018TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, January 23, 2018TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, January 10, 2018NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Wednesday, January 10, 2018REFUSAL PROCESSED BY MPU
Thursday, December 21, 2017NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Wednesday, December 20, 2017NON-FINAL ACTION WRITTEN
Saturday, December 16, 2017ASSIGNED TO EXAMINER
Tuesday, October 31, 2017APPLICATION FILING RECEIPT MAILED
Wednesday, October 25, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Thursday, October 19, 2017SN ASSIGNED FOR SECT 66A APPL FROM IB

Related Keywords

miltuximab diseases disorders auto immune oncological inflammation cancer preparations diagnosis treatment